Business Wire

Genstar Capital and TA Associates Announce Agreement to Merge Compusoft and 2020

30.6.2021 13:00:00 EEST | Business Wire | Press release

Share

Genstar Capital and TA Associates today announced that they have signed a definitive agreement to merge their portfolio companies, Compusoft, a leading international provider of specialized visual Configure, Price, Quote (“vCPQ”) software to key retail and manufacturing industries, and 2020 Technologies (“2020”), a leading provider of specialized computer-aided design (“CAD”), configure, price, quote (“CPQ”) and enterprise solutions dedicated to interior design, space planning and furniture manufacturing industries. The transaction is expected to be completed in the second half of 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210630005446/en/

Compusoft and 2020 will be combined in a merger of equals to create a leading provider of space planning and manufacturing solutions for the residential and commercial segments. The group will offer an end-to-end suite of planning, design, visualization, configuration, pricing, quoting, ERP and manufacturing solutions to consumers, retailers and suppliers across the kitchen, bathroom, office and residential furniture and commercial and residential windows & doors segments. The expansive global network will be enhanced by local expertise and deep customer relationships developed over decades. An impressive combined workforce will benefit from 65+ years of experience in customer service, catalog content, innovation and technology to bring a best-in-class offering to customers and create a platform for future growth.

Compusoft is a portfolio company of TA Associates, a leading global growth private equity firm that invested in Compusoft in 2018. 2020 is a portfolio company of Genstar Capital, a leading private equity firm focused on investments in targeted segments of the financial services, healthcare, industrials and software industries that recently acquired 2020. The newly-combined company will be majority owned by Genstar and TA.

Mark Stoever, Chief Executive Officer of 2020, said, “The merger of Compusoft and 2020 positions the combined company as a trusted provider whose suite of solutions supports designers, manufacturers and retailers. This is a transformative transaction and the support from Genstar and TA will enable us to invest in the business, new technologies and our people. We look forward to completing the transaction so we can continue to build on our companies’ unwavering commitment to innovation and customer service.”

David Tombre, Chief Executive Officer of Compusoft, said, “We are excited by the opportunity this combination presents to create a leading provider of vCPQ solutions for home and commercial spaces. Given Compusoft’s presence in Europe and 2020’s presence in North and South America, the two businesses are truly complementary. Our priority remains our customer’s success and together we will provide an enhanced offering across support, content, innovation and technology.”

Naveen Wadhera, Managing Director at TA, said, “Since TA’s investment, Compusoft has completed five acquisitions while also realizing sustained and meaningful organic growth. This growth has helped further position Compusoft as a leader, well-suited for what we believe will be a value-enhancing combination with 2020. It has been a privilege to partner with Compusoft during this expansion, and we look forward to working with the combined teams on the next phase of growth.”

Eli Weiss, Managing Director at Genstar Capital, said, “The combination of Compusoft and 2020 is a merger of equals by which there will be a number of benefits. Compusoft and 2020 are leading companies in their respective geographies, and we are confident that this merger will provide opportunities for continued organic and inorganic growth. The company is now better positioned to pursue new global opportunities that will enhance customer service and build on their strong momentum.”

The transaction is subject to customary regulatory approvals and closing conditions. Terms of the transaction were not disclosed.

Goodwin Procter LLP is serving as legal counsel and Alvarez & Marsal as financial and tax advisor to TA. Kirkland & Ellis LLP is serving as legal counsel, Alvarez & Marsal is serving as financial and tax advisor and William Blair is serving as financial advisor to Genstar.

About Compusoft

Compusoft provides visual CPQ solutions that simplify planning, configuration and visualization to power sales processes for the kitchen, bathroom, furniture and window & door industries. Compusoft’s solutions assist customers throughout the sales value-chain from end-customers through to manufacturers and are underpinned by a rich content database. Founded in 1989, Compusoft is headquartered in Sarpsborg, Norway, and serves customers in more than 100 countries with over 600 people in 18 countries across Europe, Asia-Pacific and North America. For more information, please visit www.compusoftgroup.com.

About 2020 Technologies Inc.

2020 helps professional designers, retailers and manufacturers in the interior design and furniture industries capture ideas, inspire innovation and streamline processes. By providing end-to-end solutions and a large collection of manufacturers' catalogs, 2020’s applications enable professional designers and retailers to create kitchens, bathrooms, furniture and commercial offices that look as stunning on the screen as they do in reality. 2020 solutions for furniture and cabinet manufacturers deliver a complete manufacturing operations management capability to run their factories at maximum efficiency. Founded in 1987 and headquartered in Westford, Massachusetts, 2020 employs more than 850 people with direct operations in 11 countries and supports customers in many more locations around the world through a network of value-added resellers. For more information, please visit www.2020spaces.com.

About TA Associates

TA Associates is a leading global growth private equity firm. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer and business services – the firm invests in profitable, growing companies with opportunities for sustained growth, and has invested in more than 535 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $47.5 billion in capital since its founding in 1968 and is committing to new investments at the pace of over $3 billion per year. The firm’s more than 100 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA can be found at www.ta.com.

About Genstar Capital

Genstar Capital is a leading private equity firm that has been actively investing in high quality companies for over 30 years. Based in San Francisco, Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. Together with Genstar X and all active funds, Genstar currently has approximately $33 billion of assets under management and targets investments focused on targeted segments of the financial services, healthcare, industrials, and software industries. More information about Genstar Capital can be found at www.gencap.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Compusoft
Divesh Nagarajan
+44-7400015239
divesh.nagarajan@compusoftgroup.com

For 2020 Technologies
Karen Curtis
+1-774-215-6916
karen.curtis@2020spaces.com

For TA Associates
Marcia O’Carroll
TA Associates
+ 1-617-574-6796
mocarroll@ta.com

Philip Nunes
BackBay Communications
+ 1-617-391-0792
phil.nunes@backbaycommunications.com

Amisha Mehta
BackBay Communications
+44 203 475 7551
amisha.mehta@backbaycommunications.com

For Genstar Capital
Chris Tofalli
Chris Tofalli Public Relations
914-834-4334
chris@tofallipr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye